Ionis Pharmaceuticals begins donidalorsen phase 3 trial in hereditary angioedema
Ionis Pharmaceuticals, a US-based developer of RNA-targeted therapies, has launched the OASIS-HAE phase 3 clinical trial for donidalorsen (formerly IONIS-PKK-LRx) in patients having hereditary angioedema (HAE). Donidalorsen, which is an investigational antisense drug, is designed to lower the production of prekallikrein, which has a major role in triggering inflammatory mediators pertaining to acute attacks of […]